(Q38118851)

29 August 2017

Vemurafenib and ipilimumab: new agents for metastatic melanoma (English)

1 reference

29 August 2017

0 references

1 reference

Megan Banaszynski

1

1 reference

PubMed ID

23820456

29 August 2017

Jill M Kolesar

series ordinal

2

1 reference

29 August 2017

1 July 2013

1 reference

American Journal of Health-System Pharmacy

29 August 2017

1 reference

29 August 2017

70

1 reference

29 August 2017

14

1 reference

29 August 2017

1205-1210

1 reference

29 August 2017

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

The history and future of chemotherapy for melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Distinct sets of genetic alterations in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Mutations of the BRAF gene in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

The role of BRAF V600 mutation in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

B-RAF is a therapeutic target in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

BRAF somatic mutations in malignant melanoma and melanocytic naevi

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

BRAF targeted therapy changes the treatment paradigm in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120260

31 March 2020

Identifiers

DOI

10.2146/AJHP120260

1 reference

29 August 2017

1 reference

PubMed ID

23820456